The upcoming report from Neurocrine Biosciences (NBIX) is expected to reveal quarterly earnings of $1.58 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $630.72 million, representing an increase of 22.4% year over year.The current level reflects a downward revision of 9.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ov ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Conference Call and Webcast Scheduled for Thursday, February 6SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025.The schedule for the press release and conference call / webcast is as follows: Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ET Q4 & Year-E ...

Neurocrine Biosciences (NBIX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, ...

SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the Phase 2 SAVITRI™ study of osavampator in adult subjects with MDD were announced in April 2024. "Osavampator has the po ...

Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, as well as a robust pipeline with multiple compounds in mid- to late-phase clinical development [3] Leadership Change - Dr. Ratz has joined Neurocrine after a 28-year career at Eli Lilly, where he contributed to the development and successful registration of over 25 products across various therapeutic areas [1] - He served as Senior Vice President and Head of the Drug Delivery, Device and Connected Solutions organization at Lilly, leading the design and development of drug-device combination products [1][2] - Dr. Ratz expressed excitement about contributing to Neurocrine's innovative work and making a lasting impact on patients' lives through science and discovery [2]

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at th ...

Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a Lifetime SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatme ...

Core Insights - Neurocrine Biosciences has announced the commercial availability of CRENESSITY™ (crinecerfont) in the United States as an adjunctive treatment for classic congenital adrenal hyperplasia (CAH) in patients aged four years and older [1][9][16] - CRENESSITY has been approved by the U.S. Food and Drug Administration (FDA) to help control androgen levels in patients with CAH, addressing long-standing challenges associated with high-dose steroid treatments [2][7][18] Company Overview - Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a commitment to providing life-changing therapies for patients with unmet medical needs [28] - The company has a diverse portfolio that includes FDA-approved treatments for various conditions, including CAH, and is dedicated to supporting patients through programs like Neurocrine Access Support [2][28] Product Details - CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces adrenocorticotropic hormone (ACTH) and adrenal androgens, allowing for lower doses of glucocorticoids while maintaining or improving androgen levels [8][16][30] - The product is available in capsule form (50 mg and 100 mg) and as an oral solution (50 mg/mL), with specific dosing recommendations based on patient age and weight [30] Clinical Studies - The approval of CRENESSITY was supported by the CAHtalyst™ global registrational studies, which included the largest-ever clinical trial program for classic CAH, involving 285 pediatric and adult patients [6][7][18][22] - The studies demonstrated that CRENESSITY effectively improved androgen control and allowed for the down-titration of glucocorticoids while maintaining or improving androstenedione levels [22]

Neurocrine Biosciences (NASDAQ: NBIX ) remains a key player in the biopharmaceutical sector. Its main focus is on neurological, neuroendocrine, and neuropsychiatric treatment. Since my last analysis in July 2024, NBIX’s Ingrezza, its flagship product, isMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in B ...